Medical Device Company Intelligence Reports provide a full review of the company's activities, from its origins to its latest corporate activity, including mergers and acquisitions, agreements, divestitures, major purchasing contracts and litigation. Sections are included on products, international activities and R&D, as well as a full, in-depth five year financial analysis. An introduction to each report and a full table of contents is provided for review. More than 60 Medical Device Company Intelligence Reports are currently available. Elekta AB, headquartered in Stockholm, Sweden, offers clinical solutions and services for the radiation treatment of cancer and the minimally-invasive treatment of brain disorders, including tumours, vascular disorders and functional disorders such as facial pain, epilepsy and Parkinson's disease. In fiscal 2005, Elekta's revenue rose by 9% to SKr 3.2 billion.

Elekta operates within two business areas, oncology and neurosurgery. The company's main business is oncology, sales of which increased by 16% to SKr 2.2 billion in 2005. Elekta claims to be the world's second-largest supplier of oncology products after Varian Medical Systems. It offers linear accelerators, simulators, stereotactic radiotherapy equipment, 3D dose planning systems and products for intensity-modulated radiation treatment. In April 2005, Elekta acquired Impac Medical Systems, enabling Elekta to also offer a range of medical IT systems for use in cancer care, including integrated solutions centred on image-enabled electronic medical records covering the cancer treatment process.

Elekta claims to be the market leader for devices for the radiosurgical treatment of brain disorders as a result of its Leksell Gamma Knife technology. The company's neurosurgery products also include the magnetoencephalography devices gained through the 2003 acquisition of Neuromag. In 2005, neurosurgery sales declined by 5% to SKr 977 million.